Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib
Kaelyn C. Cummins(Brigham and Women's Hospital), Nicolas C. Issa(Dana-Farber Cancer Institute), David W. Kubiak(Harvard University), Francisco M. Marty(Brigham and Women's Hospital), Matthew P. Cheng(McGill University Health Centre), Matthew S. Davids(Dana-Farber Cancer Institute)
Cited by 18
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
|New England Journal of Medicine|2020|1.4k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752